These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid. Prescrire Int; 2005 Feb; 14(75):5-9. PubMed ID: 15747448 [TBL] [Abstract][Full Text] [Related]
4. Nongranulomatous anterior uveitis associated with alendronate therapy. Salmen S; Berrueta L; Sánchez N; Montes H; Borges L Invest Clin; 2002 Mar; 43(1):49-52. PubMed ID: 11921747 [TBL] [Abstract][Full Text] [Related]
5. Adverse drug reactions in Canada. Bisphosphonates and ocular disorders. Can Fam Physician; 2004 Mar; 50():422-4. PubMed ID: 15318681 [No Abstract] [Full Text] [Related]
6. [Psychiatric side effects associated with diphosphonate treatment]. Wolffenbuttel BH; van der Klauw MM Ned Tijdschr Geneeskd; 2003 Jan; 147(1):35-7. PubMed ID: 12564297 [TBL] [Abstract][Full Text] [Related]
8. Posterior uveitis: an under-recognized adverse effect of pamidronate: 2 case reports. Haverbeke G; Pertile G; Claes C; Zeyen T Bull Soc Belge Ophtalmol; 2003; (290):71-6. PubMed ID: 14750233 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Iwamoto J; Takeda T; Sato Y Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313 [TBL] [Abstract][Full Text] [Related]
10. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Saag K; Lindsay R; Kriegman A; Beamer E; Zhou W Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063 [TBL] [Abstract][Full Text] [Related]
11. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. French DD; Margo CE Retina; 2008 Jun; 28(6):889-93. PubMed ID: 18536608 [TBL] [Abstract][Full Text] [Related]
12. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Hagino H; Nishizawa Y; Sone T; Morii H; Taketani Y; Nakamura T; Itabashi A; Mizunuma H; Ohashi Y; Shiraki M; Minamide T; Matsumoto T Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155 [TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates and ocular inflammation. Fraunfelder FW; Fraunfelder FT N Engl J Med; 2003 Mar; 348(12):1187-8. PubMed ID: 12646685 [No Abstract] [Full Text] [Related]
14. A comparison of the gastrointestinal effects of the nitrogen-containing bisphosphonates pamidronate, alendronate, and olpadronate in humans. Twiss IM; van den Berk AH; de Kam ML; Bosch JJ; Cohen AF; Vermeij P; Burggraaf J J Clin Pharmacol; 2006 Apr; 46(4):483-7. PubMed ID: 16554458 [No Abstract] [Full Text] [Related]
19. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062 [TBL] [Abstract][Full Text] [Related]
20. More on reports of esophageal cancer with oral bisphosphonate use. Shaheen NJ N Engl J Med; 2009 Apr; 360(17):1790-1; author reply 1791-2. PubMed ID: 19391257 [No Abstract] [Full Text] [Related] [Next] [New Search]